Havasi, Andrea http://orcid.org/0000-0002-8758-0823
Heybeli, Cihan http://orcid.org/0000-0001-7903-1106
Leung, Nelson
Angel-Korman, Avital
Sanchorawala, Vaishali http://orcid.org/0000-0002-6307-2445
Cohen, Oliver
Wechalekar, Ashutosh http://orcid.org/0000-0002-4406-7237
Bridoux, Frank
Jaffer, Insara
Gutgarts, Victoria
Hassoun, Hani http://orcid.org/0000-0002-2036-1749
Levinson, Maya
Rosenbaum, Cara
Milani, Paolo http://orcid.org/0000-0002-2268-9422
Palladini, Giovanni http://orcid.org/0000-0001-5994-5138
Merlini, Giampaolo http://orcid.org/0000-0001-7680-3254
Hegenbart, Ute http://orcid.org/0000-0003-1917-6746
Schönland, Stefan http://orcid.org/0000-0002-4853-5579
Veelken, Kaya
Pogrebinsky, Alexander
Doros, Gheorghe
Landau, Heather http://orcid.org/0000-0002-3152-1189
Article History
Received: 24 January 2022
Revised: 25 July 2022
Accepted: 28 July 2022
First Online: 18 August 2022
Competing interests
: VS: Research support from Celgene, Takeda, Caelum, Prothena, Janssen. Advisory boards of Regeneron, Abbvie, Janssen, Caelum; Consultancy for Pfizer. UH: Grants from Janssen, Prothena, and Pfizer. Advisory boards for Pfizer, Janssen, and Prothena. Honoraria from Janssen, Pfizer, Alnylam, and Akcea, Research funding from Janssen. SOS: Travel grants from Janssen, MSD, Prothena and Takeda, Advisory boards for Janssen and Prothena. Honoraria from Janssen, Prothena, Pfizer, and Takeda. Research funding from Sanofi and Janssen. HL: Advisory board for Janssen, Celgene, Sanofi, Takeda, Caelum, Pfizer. Honoraria from Pfizer and Sanofi. Research funding from Takeda. GP: Honoraria and advisory board of Janssen-Cilag, Honoraria Pfizer and Siemens. PM: Speaker honoraria Janssen-Cilag. Travel support from Celgene. FB: Honoraria from Astra-Zeneca and Janssen. AH: At the time of publication employed by Alnylam Pharmaceuticals. At the time of data collection, analysis and writing of the paper no disclosure.